Drug intelligence / Profile preview

risperidone + haloperidol

Development stage
Unknown
Lead developer
Janssen Pharmaceutica
Modality
Small Molecules
Administration
Oral
01

Overview

Risperidone and haloperidol are both antipsychotic medications. Risperidone is a benzisoxazole derivative, while haloperidol is a butyrophenone. Both are primarily dopamine receptor antagonists, with risperidone also acting as a serotonin 5-HT2A receptor antagonist. They are widely used in the treatment of psychiatric conditions such as schizophrenia and manic episodes associated with bipolar disorder. Clinical trials have also investigated their use in delirium, though some studies suggest they may not be more effective than placebo for this indication and can be associated with significant side effects like hyperprolactinemia and extrapyramidal symptoms.

Brand names
RisperdalHaldol
Other names
risperidone, haloperidol
02

Targets

DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD1 (Dopamine D1 Receptor)ADRA2A (α2A)DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on risperidone + haloperidol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on risperidone + haloperidol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call